J&J: Taking Stock of a Household Name BusinessWeek - Despite some near-term operating challenges, particularly within its pharmaceutical segment, we think Johnson & Johnson ( JNJ ; $58) continues to offer one of the more consistent long-term growth rates among large-cap pharma/device outfits, and a
Read The Full Article:
http://www.drilltools.org/280
Add to del.icio.us
Digg this
Post to Furl
Add to reddit
Add to myYahoo!
Powered by blogdig.net